Human Anti-COVID-19 IgM Positive Control


Quote for bulk order
SKU: N/A Category:


Product Name: Human Anti-COVID-19 IgM Positive Control

Catalog No: exo-CR4002

Immunogen: The original monoclonal antibody was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV.

Host: Human

Preparation: Antibody was expressed in HEK293F cells and purified using affinity chromatography

Applications: Positive control for COVID-19 serological detection assays

Reactivity: SARS Coronavirus,SARS Coronavirus 2, Spike RBD protein ( Catalog # 19Cov-S120)

Isotype: human IgM; kappa

Conjugation: Unconjugated

Clonality: Monoclonal

Concentration: 1mg/ml

Purification: Affinity chromatography

Storage buffer: PBS

Storage conditions: For long term storage, the antibody should be stored at -20℃ and is stable for 12 months from the date of receipt. Avoid repeated freeze-thaw cycles. For short term storage, keep at 4oC for a week should be fine.

Application Dilution: 1:1,000-1:100,000 (platform dependent, customers have to test the optimal concentration on their own platform)

Summary: The SARS-CoV / SARS-CoV-2 spike antibody [CR3022] antibody specifically binds to the receptor binding domain (RBD) of both SARS-CoV and SARS-CoV-2 with high affinity (PMID: 16796401 & 32065055). The initial characterization of the binding of this antibody was performed by ELISA and indicates potential for the development of diagnostic assays, as both virus-capture assays, or as controls in serological assays measuring immune responses to virus exposure. The original human IgG1 version of the antibody works synergistically in combination with another non-competing SARS antibody CR3014 and is a potential candidate for passive immune prophylaxis of SARS-CoV infection. This antibody may have potential as a therapeutic agent, alone or in combination with other neutralizing antibodies for treatment of 2019-nCoV infections (Tian et al., 2020).


Certificate of Analysis